Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × Hepatectomy × Clear all
NCT03844750 2025-12-31

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

University of California, San Francisco

Phase 2 Terminated
6 enrolled 12 charts
Gastrointestinal

Colorectal Neoplasms

NCT03801915 2023-03-21

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡